| Literature DB >> 20351194 |
Daphné A Schmid1, Melita B Irving, Vilmos Posevitz, Michael Hebeisen, Anita Posevitz-Fejfar, J-C Floyd Sarria, Raquel Gomez-Eerland, Margot Thome, Ton N M Schumacher, Pedro Romero, Daniel E Speiser, Vincent Zoete, Olivier Michielin, Nathalie Rufer.
Abstract
Protective adaptive immune responses rely on TCR-mediated recognition of Ag-derived peptides presented by self-MHC molecules. However, self-Ag (tumor)-specific TCRs are often of too low affinity to achieve best functionality. To precisely assess the relationship between TCR-peptide-MHC binding parameters and T cell function, we tested a panel of sequence-optimized HLA-A(*)0201/NY-ESO-1(157-165)-specific TCR variants with affinities lying within physiological boundaries to preserve antigenic specificity and avoid cross-reactivity, as well as two outliers (i.e., a very high- and a low-affinity TCR). Primary human CD8 T cells transduced with these TCRs demonstrated robust correlations between binding measurements of TCR affinity and avidity and the biological response of the T cells, such as TCR cell-surface clustering, intracellular signaling, proliferation, and target cell lysis. Strikingly, above a defined TCR-peptide-MHC affinity threshold (K(D) < approximately 5 muM), T cell function could not be further enhanced, revealing a plateau of maximal T cell function, compatible with the notion that multiple TCRs with slightly different affinities participate equally (codominantly) in immune responses. We propose that rational design of improved self-specific TCRs may not need to be optimized beyond a given affinity threshold to achieve both optimal T cell function and avoidance of the unpredictable risk of cross-reactivity.Entities:
Mesh:
Substances:
Year: 2010 PMID: 20351194 DOI: 10.4049/jimmunol.1000173
Source DB: PubMed Journal: J Immunol ISSN: 0022-1767 Impact factor: 5.422